Memantine LEK

Nazione: Unione Europea

Lingua: danese

Fonte: EMA (European Medicines Agency)

Principio attivo:

memantinhydrochlorid

Commercializzato da:

Pharmathen S.A.

Codice ATC:

N06DX01

INN (Nome Internazionale):

memantine

Gruppo terapeutico:

Psychoanaleptics, , Andre demensmedicin

Area terapeutica:

Alzheimers sygdom

Indicazioni terapeutiche:

Behandling af patienter med moderat til svær Alzheimers sygdom.

Dettagli prodotto:

Revision: 5

Stato dell'autorizzazione:

autoriseret

Data dell'autorizzazione:

2013-04-21

Foglio illustrativo

Skip to main content [European Medicines Agency]
Menu *
EMA WEBSITE TEMPORARILY UNAVAILABLE
This website is currently unavailable due to essential maintenance.
EMERGENCY CONTACT DETAILS
To report a potentially serious problem with a centrally authorised
medicine, call our product emergency hotline on [phone].
To report a product quality defect, including a suspected defect, of a
centrally authorised medicine that could result in a recall or
abnormal restriction on supply, marketing or manufacturing
authorisation holders can call [phone] outside business
hours.
The details of your call may be documented, including personal data if
you provide them (such as your name, contact details and nature of the
issue raised), in accordance with our privacy statement. You can
consult our privacy statement at
https://www.ema.europa.eu/en/about-us/legal/general-privacy-statement
[/en/about-us/legal/general-privacy-statement] once the website is
back online.
RSS feed Twitter YouTube LinkedIn
© 1995-2020 European Medicines Agency
European Union agencies network [European Union agencies network]
An agency of the European Union [European Union flag]

Scheda tecnica

Skip to main content [European Medicines Agency]
Menu *
EMA WEBSITE TEMPORARILY UNAVAILABLE
This website is currently unavailable due to essential maintenance.
EMERGENCY CONTACT DETAILS
To report a potentially serious problem with a centrally authorised
medicine, call our product emergency hotline on [phone].
To report a product quality defect, including a suspected defect, of a
centrally authorised medicine that could result in a recall or
abnormal restriction on supply, marketing or manufacturing
authorisation holders can call [phone] outside business
hours.
The details of your call may be documented, including personal data if
you provide them (such as your name, contact details and nature of the
issue raised), in accordance with our privacy statement. You can
consult our privacy statement at
https://www.ema.europa.eu/en/about-us/legal/general-privacy-statement
[/en/about-us/legal/general-privacy-statement] once the website is
back online.
RSS feed Twitter YouTube LinkedIn
© 1995-2020 European Medicines Agency
European Union agencies network [European Union agencies network]
An agency of the European Union [European Union flag]